Literature DB >> 17376624

Cardiac troponin I for accurate evaluation of cardiac status in myopathic patients.

Tsuyoshi Matsumura1, Toshio Saito, Harutoshi Fujimura, Susumu Shinno.   

Abstract

BACKGROUND: Brain natriuretic peptide (BNP) and left ventricular ejection fraction (LVEF) are standard indexes for cardiac function. However, they can not reveal myocardial damage directly and they often remain normal even in advanced cardiomyopathy in immobilized patients. Myocardial markers such as MB type of creatine kinase (CK-MB), heart-type fatty acid binding protein (H-FABP) and cardiac troponins are expected to evaluate active myocardial degeneration. However, their availabilities in these patients have not been examined yet.
METHODS: Participants were 129 patients with dystrophinopathies; 100 Duchenne muscular dystrophy (DMD), 25 Becker muscular dystrophy (BMD) and 4 DMD/BMD carriers. Various serological cardiac indexes, including CK-MB, H-FABP, cardiac troponin I (cTnI), BNP and LVEF were measured and statistical analysis was done.
RESULTS: CK-MB and H-FABP was highly associated with creatine kinase (CK). On the contrary, cTnI, BNP and LVEF were independent from CK. In DMD, relatively high cTnI values were observed in patients with motor ability of rowing wheelchair and in their second decade. BNP and LVEF was strongly correlated. However, cTnI was independent from LVEF and only weak correlation could be detected between cTnI and BNP.
CONCLUSION: cTnI had been proven to be expressed in myocardium exclusively. Our results also certified that cTnI can assess cardiac degeneration independently from skeletal muscle degeneration and is practical index even in myopathic patients. Our findings also suggested that cardiac degeneration was preceded to functional impairment in many cases. It indicated that cTnI enable us to detect early stage of cardiac degeneration and initiate intervention at proper stage.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17376624     DOI: 10.1016/j.braindev.2007.01.009

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  11 in total

1.  Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients.

Authors:  Yetrib Hathout; Ramya L Marathi; Sree Rayavarapu; Aiping Zhang; Kristy J Brown; Haeri Seol; Heather Gordish-Dressman; Sebahattin Cirak; Luca Bello; Kanneboyina Nagaraju; Terry Partridge; Eric P Hoffman; Shin'ichi Takeda; Jean K Mah; Erik Henricson; Craig McDonald
Journal:  Hum Mol Genet       Date:  2014-07-15       Impact factor: 6.150

2.  Troponin I Levels Correlate with Cardiac MR LGE and Native T1 Values in Duchenne Muscular Dystrophy Cardiomyopathy and Identify Early Disease Progression.

Authors:  Sonia Voleti; Laura Olivieri; Karin Hamann; Heather Gordish-Dressman; Christopher Spurney
Journal:  Pediatr Cardiol       Date:  2020-05-31       Impact factor: 1.655

3.  Tranilast for advanced heart failure in patients with muscular dystrophy: a single-arm, open-label, multicenter study.

Authors:  Tsuyoshi Matsumura; Hiroya Hashimoto; Masahiro Sekimizu; Akiko M Saito; Yasufumi Motoyoshi; Akinori Nakamura; Satoshi Kuru; Takayasu Fukudome; Kazuhiko Segawa; Toshiaki Takahashi; Takuhisa Tamura; Tetsuo Komori; Chigusa Watanabe; Masanori Asakura; Koichi Kimura; Yuko Iwata
Journal:  Orphanet J Rare Dis       Date:  2022-05-16       Impact factor: 4.303

Review 4.  Current understanding and management of dilated cardiomyopathy in Duchenne and Becker muscular dystrophy.

Authors:  Rita Wen Kaspar; Hugh D Allen; Federica Montanaro
Journal:  J Am Acad Nurse Pract       Date:  2009-05

5.  Duchenne Muscular Dystrophy Mice and Men: Can Understanding a Genetic Cardiomyopathy Inform Treatment of Other Myocardial Diseases?

Authors:  Jill A Rafael-Fortney; Jessica A Chadwick; Subha V Raman
Journal:  Circ Res       Date:  2016-04-01       Impact factor: 17.367

6.  Acute AT1R blockade prevents isoproterenol-induced injury in mdx hearts.

Authors:  Tatyana A Meyers; Jackie A Heitzman; Aimee M Krebsbach; Lauren M Aufdembrink; Robert Hughes; Alessandro Bartolomucci; DeWayne Townsend
Journal:  J Mol Cell Cardiol       Date:  2019-01-19       Impact factor: 5.000

7.  Duchenne muscular dystrophy patients: troponin leak in asymptomatic and implications for drug toxicity studies.

Authors:  Larry W Markham; Jonathan H Soslow; Aryaz Sheybani; Kim Crum; Frank J Raucci; William B Burnette
Journal:  Pediatr Res       Date:  2021-08-24       Impact factor: 3.756

8.  Elevated plasma levels of cardiac troponin-I predict left ventricular systolic dysfunction in patients with myotonic dystrophy type 1: A multicentre cohort follow-up study.

Authors:  Mark J Hamilton; Yvonne Robb; Sarah Cumming; Helen Gregory; Alexis Duncan; Monika Rahman; Anne McKeown; Catherine McWilliam; John Dean; Alison Wilcox; Maria E Farrugia; Anneli Cooper; Josephine McGhie; Berit Adam; Richard Petty; Cheryl Longman; Iain Findlay; Alan Japp; Darren G Monckton; Martin A Denvir
Journal:  PLoS One       Date:  2017-03-21       Impact factor: 3.240

Review 9.  Cardiac Pathophysiology and the Future of Cardiac Therapies in Duchenne Muscular Dystrophy.

Authors:  Tatyana A Meyers; DeWayne Townsend
Journal:  Int J Mol Sci       Date:  2019-08-22       Impact factor: 5.923

Review 10.  Current state of cardiac troponin testing in Duchenne muscular dystrophy cardiomyopathy: review and recommendations from the Parent Project Muscular Dystrophy expert panel.

Authors:  Christopher F Spurney; Deborah Ascheim; Lawrence Charnas; Linda Cripe; Kan Hor; Nicholas King; Kathi Kinnett; Elizabeth M McNally; John-Michael Sauer; Lee Sweeney; Chet Villa; Larry W Markham
Journal:  Open Heart       Date:  2021-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.